Kyle Doherty

Treatment with linvoseltamab provided durable efficacy for patients with relapsed/refractory multiple myeloma.

New or worsening anemia may not reduce the clinical benefit derived from ruxolitinib treatment in patients with myelofibrosis.

Perioperative chemotherapy with FLOT improved overall survival in patients with resectable esophageal cancer compared with neoadjuvant chemoradiation with CROSS.

Asciminib led to a superior 48-week major molecular response rate compared with investigator-selected tyrosine kinase inhibitors for Ph-positive chronic phase chronic myeloid leukemia.

Community urology practices have routinely used darolutamide in both doublet and triplet regimens to treat metastatic hormone-sensitive prostate cancer.

A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.

Enzalutamide with and without leuprolide improves rates of undetectable PSA levels compared with leuprolide alone in castration-sensitive prostate cancer.

The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.

Patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer treated with TAR-200 exhibited a high complete response rate to the treatment.

Patients with newly diagnosed and recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer treated with UGN-102 displayed meaningful and similar responses and disease-free survival regardless of whether they underwent surgery.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

As part of a survey of practicing oncologists in the United States, clinicians may have ethical concerns around using artificial intelligence in cancer care.

Patients with early-stage breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor provided a greater invasive disease-free survival benefit compared with nonsteroidal aromatase inhibitor therapy alone.

Progression-free and overall survival benefits were obtained with MRD-guided ibrutinib plus venetoclax when compared with fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Venetoclax provided long-lasting responses in patients with relapsed/refractory chronic lymphocytic leukemia.

A next-generation stool DNA test had higher sensitivity for CRC and advanced precancerous lesions but lower specificity for advanced neoplasia compared with a fecal immunochemical test.

Disease-free survival rates were extended in patients with upper tract urothelial cancer treated with adjuvant chemotherapy after nephroureterectomy compared with those who underwent surveillance.

A biologics license application has been accepted by the FDA for first-line tislelizumab plus chemotherapy for gastric/gastroesophageal junction cancer.

Lurbinectedin confers greater activity with a superior safety profile when compared with topotecan in a subset of patients with small cell lung cancer.

Patients with recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype did not derive a survival benefit with trabectedin when compared with chemotherapy.

The NCCN has published its first set of treatment recommendations patients with for neuroblastoma.

The FDA received a sBLA that is seeking approval of D-VRd for the treatment of transplant-eligible patients with newly diagnosed multiple myeloma.

Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.

The rate of initiating immunotherapy towards the end of life in patients with advanced cancers, including renal cell carcinoma, melanoma, and non-small cell lung cancer, is increasing over time.

A new drug application for SH-105 has been accepted by the FDA to potentially treat patients with breast and ovarian cancer.

Most biomarkers in subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p) derived benefit from zanubrutinib vs bendamustine plus rituximab.

The overall response rate with ibrutinib plus venetoclax was 82% vs 74% with ibrutinib plus placebo.

The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma.

New ASCO guidelines recommend trilaciclib for patients with untreated or previously treated extensive-stage small cell lung cancer who are receiving chemotherapy or chemoimmunotherapy.